For most people, yes. Semaglutide, the active ingredient in both Ozempic and Wegovy, is designed as a long-term medication. The FDA specifically approved Wegovy (the weight management version) to “reduce excess body weight and maintain weight reduction long term,” and Ozempic carries similar expectations for ongoing blood sugar control in type 2 diabetes. Stopping the medication typically leads to weight regain and, for diabetic patients, rising blood sugar levels.
That doesn’t mean every person stays on it forever, but the medical framework treats it much like blood pressure medication: it works while you take it.
What Happens When You Stop
The clearest evidence comes from discontinuation data. People who stop taking semaglutide regain roughly two-thirds of the weight they lost, and 50 to 75 percent of users stop within the first year. This pattern isn’t unique to semaglutide. It reflects something fundamental about how the body responds to weight loss: hormonal signals that drive hunger and slow metabolism ramp back up once the drug is no longer suppressing them.
For people using Ozempic for type 2 diabetes, stopping carries its own risks. Blood sugar levels typically climb back toward pre-treatment levels, and the cardiovascular and kidney protections the drug provides disappear along with it. Unlike weight loss, where some people retain a portion of their results through sustained lifestyle changes, blood sugar management in type 2 diabetes tends to revert more completely without medication.
Why Doctors Compare It to Blood Pressure Medication
The World Obesity Federation classifies obesity as a “chronic relapsing progressive disease process,” placing it in the same category as conditions like hypertension and type 2 diabetes itself. The logic is straightforward: if the underlying biology doesn’t resolve, removing the treatment brings back the problem. Nobody asks whether blood pressure medication is “for life” with surprise, because the expectation is baked in. Obesity medicine is moving toward that same framework, even though many patients and insurers still think of weight loss drugs as temporary interventions.
This framing matters because it shapes expectations. If you view semaglutide as a short course of treatment, regaining weight afterward feels like failure. If you view it as managing an ongoing condition, continuation makes more sense.
What Long-Term Use Looks Like
The standard dosing protocol for weight management starts low (0.25 mg weekly) and escalates over several months to a maintenance dose of 2.4 mg weekly. That 2.4 mg dose is the maintenance dose. There is no established protocol for stepping down to a lower dose once you hit your target weight. If you can’t tolerate the full dose, guidelines suggest temporarily dropping to 1.7 mg for four weeks before trying again, but if you permanently can’t tolerate it, the recommendation is to discontinue entirely.
For Ozempic prescribed for diabetes, the dosing ceiling is lower (up to 2 mg weekly), but the same principle applies: you stay on a therapeutic dose indefinitely.
Safety Over Multiple Years
The SELECT trial, one of the largest and longest studies of semaglutide, tracked participants for over four years. People taking semaglutide actually had fewer serious adverse events than those on placebo across every weight category studied. The rates of serious problems per 100 person-years of observation were consistently lower in the semaglutide group, ranging from about 43 to 51 events per 100 person-years compared to 50 to 61 in the placebo group.
That said, more people on semaglutide discontinued the drug than those on placebo, largely due to gastrointestinal side effects like nausea and diarrhea. These side effects are most common during the dose-escalation phase and tend to improve, but for some people they never fully resolve. Interestingly, discontinuation rates were higher among people with lower starting BMIs, suggesting that leaner individuals may be more sensitive to side effects or less motivated to push through them.
What we don’t yet have is data spanning decades. Semaglutide was approved for diabetes in 2017 and for weight management in 2021, so the longest real-world use is still under ten years. The multi-year trial data is reassuring, but people starting the drug in their 30s or 40s are making a commitment that extends well beyond what clinical trials have measured.
Can Some People Eventually Stop?
There’s no clinical roadmap for successfully tapering off semaglutide, but some people do stop and keep a meaningful portion of their weight loss. The ones who fare best tend to have made substantial changes to eating habits and physical activity while on the medication, using the appetite suppression as a window to build new patterns. Even then, most regain some weight.
Some doctors experiment with lower doses or less frequent injections as a compromise, but this is off-label and not supported by published dosing protocols. The formal guidance is binary: you’re on the maintenance dose or you’re off the drug.
For type 2 diabetes patients, stopping is a harder case. A small number of people who lose significant weight may see their blood sugar normalize enough to consider discontinuation under close monitoring, but this depends heavily on how advanced the disease was before treatment and how much pancreatic function remains. Most continue the medication or switch to an alternative.
The Cost and Access Question
If semaglutide is a lifelong medication, cost becomes a central issue. Without insurance coverage, the monthly price runs over $1,000. Insurance coverage varies widely: diabetes indications are more commonly covered than weight management, and many plans impose step therapy requirements or periodic reauthorization. The prospect of paying for a medication indefinitely, with the knowledge that stopping means losing most of its benefits, is a significant factor in the 50 to 75 percent discontinuation rate within the first year. Not everyone who stops does so because the drug didn’t work. Many stop because they can’t sustain the cost or lose coverage.
This creates a practical tension. The medical evidence says long-term use produces better outcomes. The financial reality means many people will use it intermittently or stop altogether, cycling through weight loss and regain in a pattern that may carry its own health risks.